Literature DB >> 24661533

Group B meningococcal vaccine: recommendations for UK use.

Andrew J Pollard1, Andrew Riordan2, Mary Ramsay3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24661533     DOI： 10.1016/S0140-6736(14)60226-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.

Authors:  Dan M Granoff; Isabella Costa; Monica Konar; Serena Giuntini; Koen K A Van Rompay; Peter T Beernink
Journal:  J Infect Dis       Date:  2015-02-12       Impact factor: 5.226

2.  Using linked birth, notification, hospital and mortality data to examine false-positive meningococcal disease reporting and adjust disease incidence estimates for children in New South Wales, Australia.

Authors:  A Gibson; L Jorm; P McIntyre
Journal:  Epidemiol Infect       Date:  2015-01-09       Impact factor: 4.434

3.  An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.

Authors:  Gunnstein Norheim; Holly Sanders; Jardar W Mellesdal; Idunn Sundfør; Hannah Chan; Carina Brehony; Caroline Vipond; Chris Dold; Rory Care; Muhammad Saleem; Martin C J Maiden; Jeremy P Derrick; Ian Feavers; Andrew J Pollard
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

4.  Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance.

Authors:  Martin C J Maiden; Jenny M MacLennan
Journal:  Clin Infect Dis       Date:  2014-07-28       Impact factor: 9.079

5.  Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.

Authors:  David Pace; Ameneh Khatami; Jennifer McKenna; Danielle Campbell; Simon Attard-Montalto; Jacqueline Birks; Merryn Voysey; Catherine White; Adam Finn; Emma Macloed; Saul N Faust; Alison Louise Kent; Paul T Heath; Ray Borrow; Matthew D Snape; Andrew J Pollard
Journal:  BMJ       Date:  2015-04-01

Review 6.  Meningococcal B vaccine and the vision of a meningitis free world.

Authors:  A Bianchi; S Fantoni; A Prugnola
Journal:  J Prev Med Hyg       Date:  2015-08-31

Review 7.  Meningococcal Vaccinations.

Authors:  Nancy Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2016-04-16

8.  Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.

Authors:  S Glennie; J F Gritzfeld; S H Pennington; M Garner-Jones; N Coombes; M J Hopkins; C F Vadesilho; E N Miyaji; D Wang; A D Wright; A M Collins; S B Gordon; D M Ferreira
Journal:  Mucosal Immunol       Date:  2015-04-29       Impact factor: 7.313

9.  Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.

Authors:  Andrew Stawasz; Liping Huang; Paige Kirby; David Bloom
Journal:  Front Public Health       Date:  2020-07-10

10.  Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of Neisseria meningitidis.

Authors:  María Victoria Humbert; Miao-Chiu Hung; Renee Phillips; Charlene Akoto; Alison Hill; Wei-Ming Tan; John Edward Heckels; Myron Christodoulides
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.